

Institutional Conflict of Interest Public Disclosures as of June 5, 2024 (if required for public disclosure) - Typically updated quarterly

ID	Human Subjects Research Title	IRB	Name of Conflicted	Business Entity	Nature of Financial Interest	Approximate Dollar Value
ICI_00026637	A Phase 1b/2 Study of Abemaciclib in Combination with Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors and Abemaciclib in Combinatio	IRB_00166698	Dr. Jamie Dwyer, Associate Dean of Clinical Research	Eli Lilly and Company	remuneration	\$5,000-\$9,999
ICI_00009415	A Phase I/II Clinical Trial to Determine Safety and Feasibility of Using an Acellular Amniotic Fluid Application to Expedite Healing in Chronic Wounds.	IRB_00128708	The Department of Internal Medicine and The University of Utah	Eliksa	equity	value cannot be readily determined
ICI_00012891	A Phase I/II Double-Blinded Randomized Prospective Study of Sterile Amniotic Fluid Filtrate Epidural Injection for the treatment of Lumbosacral Radicular Pain due to Spinal Stenosis: The SAFE Trial (Improving Safety and Outcomes in the Treatment of Pain	IRB_00131761	The Department of Internal Medicine and The University of Utah	Eliksa	equity	value cannot be readily determined
ICI_00016178	A Phase I/II Randomized Double-Blinded Placebo-Controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Sterile Filtered Amniotic Fluid as a Treatment for COVID-19 Patients	IRB_00132922	The Department of Internal Medicine and The University of Utah	Eliksa	equity	value cannot be readily determined
ICI_00012917	A Phase I/II Randomized Double-Blinded Standard of Care (Corticosteroid) vs. Sterile Amniotic Fluid for Osteoarthritis	IRB_00128491	The Department of Internal Medicine and The University of Utah	Eliksa	equity	value cannot be readily determined
ICI_00021908	AbbVie M22-947 (SIRB) >> A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma	IRB_00158591	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00018025	Alliance A051301 (CIRB)>>A Randomized Double-Blind Phase III Study of Ibrutinib during and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtyp	IRB_00102756	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00029153	Alliance A031801 (CIRB) >> A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCaL)	IRB_00153119	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Exelixis	remuneration	\$80,001 to \$99,999
ICI_00018029	Alliance A041702 (NCI CIRB) >> A Randomized Phase Iii Study Of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax And Obinutuzumab In Untreated Older Patients (≥ 70 Years Of Age) With Chronic Lymphocytic Leukemia (CLL)	IRB_00120440	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00018051	Alloimmunization Rates in Patients with Multiple Myeloma Treated with Daratumumab	IRB_00134965	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00029144	AtezCab: A Phase II Study of Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Non-Measurable Disease	IRB_00143814	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Exelixis	remuneration	\$80,001 to \$99,999
ICI_00029684	Birth Tissues for Translational Research Studies	IRB_00036454	The University of Utah Dr. John Phillips, CellReGen Program Director and Director of the University of Utah Health Sciences Center (HSC) Core Research Facilities Jan Pierce, Senior Director of the CellReGen Program Director	Eliksa Eliksa Eliksa	intellectual property intellectual property intellectual property	value cannot be readily determined value cannot be readily determined value cannot be readily determined
ICI_00018869	Breast MRgFUS: A Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System	IRB_00148669	The University of Utah	The University of Utah	intellectual property	value cannot be readily determined
ICI_00029146	CaboLu: A Phase Ib Dose-Escalation Study of Cabozantinib in Combination with Lutetium-177 (177Lu)-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)	IRB_00157278	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Exelixis	remuneration	\$80,001 to \$99,999
ICI_00029148	CaboMain: Phase 2 Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors	IRB_00165978	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Exelixis	remuneration	\$80,001 to \$99,999
ICI_00029147	Cabozantinib plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)	IRB_00104688	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Exelixis	remuneration	\$80,001 to \$99,999

Institutional Conflict of Interest Public Disclosures as of June 5, 2024 (if required for public disclosure) - Typically updated quarterly

ID	Human Subjects Research Title	IRB	Name of Conflicted	Business Entity	Nature of Financial Interest	Approximate Dollar Value
ICI_00018027	Cancer Risk and Prevention in Lynch Syndrome	IRB_00106878	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00018028	Celgene BB2121-MM-003>>A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (KarMMA-3)	IRB_00116779	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00029270	CR_1/16/2024 12:34 PM - Alliance A021602 (NCI CIRB)>>Randomized, Double-Blinded Phase III Study Of Cabozantinib Versus Placebo In Patients With Advanced Neuroendocrine Tumors After Progression On Everolimus (Cabinet)	IRB_00130361	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Exelixis	remuneration	\$80,001 to \$99,999
ICI_00018014	CR_1/19/2022 3:26 PM - ECOG-ACRIN EAA181 (CIRB): Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma Not Intended For Early Autologous Transplantation	IRB_00139305	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00029535	CR_1/30/2024 10:22 AM - A Retrospective Analysis of treatment in Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant	IRB_00161493	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00018243	CR_1/31/2022 9:53 AM - SWOG EA9161 (NCI CIRB)>> A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)	IRB_00120182	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00028066	CR_10/25/2023 1:56 PM - A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients with Fused in Sarcoma Mutations (FUS-ALS)	IRB_00144685	Dr. Jamie Dwyer, Associate Dean of Clinical Research	Ionis Pharmaceuticals	remuneration	\$20,000-\$39,999
ICI_00024153	CR_2/14/2023 11:59 AM - Loxo Oncology LOXO-BTK-20019 (sIRB) >> A Phase 3 Open-Label, Randomized Study of LOXO- 305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)	IRB_00149894	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00018730	CR_2/18/2022 9:22 AM - Monitoring and Stabilizing Behavioral Rhythms to Improve Mental Health	IRB_00098927	The University of Utah	HealthRhythm	gift to the institution	greater than \$100,000
ICI_00014122	CR_2/8/2021 9:21 AM - A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY FOR THE TREATMENT OF OCULAR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) WITH PROCESSED AMNIOTIC FLUID (pAF) DROPS	IRB_00103515	The Department of Internal Medicine and The University of Utah	Eliksa	equity	value cannot be readily determined
ICI_00011438	CR_5/15/2020 12:03 PM - Sinonasal Tissue Repository	IRB_00074325	The University of Utah	Glycomira Therapeutics	equity	value cannot be readily determined
ICI_00019741	CR_5/3/2022 12:52 PM - CRISPR Therapeutics AG CRSP-ONC-003 >> A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects with Advanced,	IRB_00133621	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00026323	CR_6/26/2023 10:52 AM - An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy	IRB_00078916	Dr. Jamie Dwyer, Associate Dean of Clinical Research	Ionis Pharmaceuticals	remuneration	\$20,000-\$39,999
ICI_00020808	CR_7/6/2022 8:31 AM - CRISPR CRSP-ONC-004 >> A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects With Relapsed or Refra	IRB_00135834	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00013877	Determining the effectiveness of the Hope4Utah program: A school-based suicide intervention	IRB_00139566	The University of Utah	Wheeler Foundation Fund	gift to the institution	greater than \$100,000

Institutional Conflict of Interest Public Disclosures as of June 5, 2024 (if required for public disclosure) - Typically updated quarterly

ID	Human Subjects Research Title	IRB	Name of Conflicted	Business Entity	Nature of Financial Interest	Approximate Dollar Value
ICI_00018042	ECOG-ACRIN EAA173 (NCI CIRB)>>Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)	IRB_00128092	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00029156	ETCTN 10104 (NCI CIRB)>>A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer	IRB_00110264	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Exelixis	remuneration	\$80,001 to \$99,999
ICI_00020295	ETCTN 10483 (NCI CIRB) >> Phase IB Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors For Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations	IRB_00155838	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00029163	ETCTN 10556 (NCI CIRB) >> Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma	IRB_00172627	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Exelixis	remuneration	\$80,001 to \$99,999
ICI_00028819	ETCTN 10559 (CIRB) >> Phase II Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with an FGFR-TACC Gene Fusion	IRB_00174118	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00029140	Exelixis XL092-001>>A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors	IRB_00127958	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Exelixis	remuneration	\$80,001 to \$99,999
ICI_00029142	Exelixis XL184-021>>A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors	IRB_00102829	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Exelixis	remuneration	\$80,001 to \$99,999
ICI_00029143	Exelixis XL184-315 >> A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer	IRB_00137912	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Exelixis	remuneration	\$80,001 to \$99,999
ICI_00017593	Janssen 17000139BLC2002 (SIRB) >>A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical C	IRB_00148979	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00027174	Janssen 17000139BLC3002 >> A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naï	IRB_00169620	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00018026	Janssen 54767414AMY3001>>A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared with CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis.	IRB_00102833	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00018032	Janssen 54767414MMY3021>>A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Ce	IRB_00123033	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00029686	Janssen 56021927PCR3020 (SIRB) >> A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prosta	IRB_00174856	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00018560	Janssen 64007957MMY3001 (SIRB) >> A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Partic	IRB_00148976	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000

Institutional Conflict of Interest Public Disclosures as of June 5, 2024 (if required for public disclosure) - Typically updated quarterly

ID	Human Subjects Research Title	IRB	Name of Conflicted	Business Entity	Nature of Financial Interest	Approximate Dollar Value
ICI_00023641	Janssen 64407564MMY3002 >> A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone	IRB_00162354	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00018052	Janssen 67652000PCR3002>>A Phase III Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious GermL	IRB_00138516	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00029701	Janssen 68284528MMY2003 (sIRB) >> A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma (CARTITUDE-2)	IRB_00174406	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00021589	Janssen 69086420PCR1001 >> A Phase 1 Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hk2) for Advanced Prostate Cancer	IRB_00158165	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00018050	Janssen 73841937NSC1001>>An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody	IRB_00135665	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00018058	Janssen 75229414MPC1001 >> A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer	IRB_00146419	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00018045	Janssen JNJ-68284528MMY3002 >> A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (Pvd) or Daratumumab, Pomalidomide and Dexametha	IRB_00130881	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00024371	Janssen Research & Development 61186372NSC2002 >> Phase II, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer	IRB_00163063	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00029343	Longitudinal Multi-Center Chart Review Study and Consortium for Multiple Myeloma (eMMPower)	IRB_00174824	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00018056	Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients with CLL/SLL	IRB_00141704	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00018040	Novartis CVAY736Y2102 >> Phase Ib open-label study of VAY736 and ibrutinib in patients with chronic lymphocytic leukemia (CLL) on ibrutinib therapy	IRB_00126007	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00018059	NRG GU006 (NCI CIRB)>>A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer	IRB_00118912	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00019649	NRG GU009 (CIRB) >> Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy For Higher Genomic Risk with Radiation (PREDICT-RT)	IRB_00152800	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000

Institutional Conflict of Interest Public Disclosures as of June 5, 2024 (if required for public disclosure) - Typically updated quarterly

ID	Human Subjects Research Title	IRB	Name of Conflicted	Business Entity	Nature of Financial Interest	Approximate Dollar Value
ICI_00022770	PBI-AMD-001 - PHASE 1/2a DOSE ESCALATION SAFETY STUDY OF VOY-101 IN SUBJECTS WITH ADVANCED NON-NEOVASCULAR AGE-RELATED MACULAR DEGENERATION	IRB_00160759	The University of Utah	The University of Utah	intellectual property	value cannot be readily determined
			Dr. Gregory Hageman, Executive Director of Moran's Steele Center for Translational Medicine (SCTM)	Perceive Biotherapeutics	equity & remuneration	value cannot be readily determined
			Dr. Randall Olson, Chair of the Department of Ophthalmology and Visual Sciences and CEO of the John A. Moran Eye Center	Perceive Biotherapeutics	equity	value cannot be readily determined
ICI_00018024	PCCTC c16-168: BRCAaway >>A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects	IRB_00101708	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00029337	Real-World Effectiveness of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRD) and Bortezomib, Lenalidomide, and Dexamethasone (VRD) as First-Line Treatment Among Transplant Eligible Newly Diagnosed Multiple Myeloma Patients	IRB_00174531	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00029154	Roche WO41994 >> A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib Versus Cabozantinib Alone in Patients with Inoperable, Locally Advanced, or Metastatic Ren	IRB_00135676	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Exelixis	remuneration	\$80,001 to \$99,999
ICI_00029155	SWOG S1500 (CIRB)>>A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET	IRB_00092539	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Exelixis	remuneration	\$80,001 to \$99,999
ICI_00018044	SWOG S1803 (CIRB) >> Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Du	IRB_00130745	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00029157	SWOG S2101 (CIRB) >> Biomarker Stratified Cabozantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO refractory Melanoma or HNSCC) Stratified by	IRB_00161033	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Exelixis	remuneration	\$80,001 to \$99,999
ICI_00029152	SWOG S2200 (NCI CIRB) >> A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)	IRB_00159592	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Exelixis	remuneration	\$80,001 to \$99,999